The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN.
Participants greater than or equal to (>=) 18 years of age.
Participants who signed the written informed consent form (ICF).
Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label;
Participants who received treatment with a drug under clinical development/ investigation within 3 months prior to baseline.
Participants who received nemolizumab previously.
Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.